Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study / Chatzikonstantinou, T.; Kapetanakis, A.; Scarfo, L.; Karakatsoulis, G.; Allsup, D.; Cabrero, A. A.; Andres, M.; Antic, D.; Baile, M.; Baliakas, P.; Bron, D.; Capasso, A.; Chatzileontiadou, S.; Cordoba, R.; Correa, J. -G.; Cuellar-Garcia, C.; De Paoli, L.; De Paolis, M. R.; Del Poeta, G.; Demosthenous, C.; Dimou, M.; Donaldson, D.; Doubek, M.; Efstathopoulou, M.; Eichhorst, B.; El-Ashwah, S.; Enrico, A.; Espinet, B.; Farina, L.; Ferrari, A.; Foglietta, M.; Frederiksen, H.; Furstenau, M.; Garcia-Marco, J. A.; Garcia-Serra, R.; Gentile, M.; Gimeno, E.; Glenthoj, A.; Gomes da Silva, M.; Gutwein, O.; Hakobyan, Y. K.; Herishanu, Y.; Hernandez-Rivas, J. A.; Herold, T.; Innocenti, I.; Itchaki, G.; Jaksic, O.; Janssens, A.; Kalashnikova, Оb.; Kalicinska, E.; Karlsson, L. K.; Kater, A. P.; Kersting, S.; Labrador, J.; Lad, D.; Laurenti, L.; Levin, M. -D.; Lista, E.; Lopez-Garcia, A.; Malerba, L.; Marasca, R.; Marchetti, M.; Marquet, J.; Mattsson, M.; Mauro, F. R.; Milosevic, I.; Miras, F.; Morawska, M.; Motta, M.; Munir, T.; Murru, R.; Niemann, C. U.; Rodrigues, R. N.; Olivieri, J.; Orsucci, L.; Papaioannou, M.; Pavlovsky, M. A.; Piskunova, I.; Popov, V. M.; Quaglia, F. M.; Quaresmini, G.; Qvist, K.; Reda, G.; Rigolin, G. M.; Ruchlemer, R.; Saghumyan, G.; Shrestha, A.; Simkovic, M.; Spacek, M.; Sportoletti, P.; Stanca, O.; Stavroyianni, N.; Tadmor, T.; Te Raa, D.; Tonino, S. H.; Trentin, L.; Van Der Spek, E.; van Gelder, M.; van Kampen, R.; Varettoni, M.; Visentin, A.; Vitale, C.; Wasik-Szczepanek, E.; Wrobel, T.; San Segundo, L. Y.; Yassin, M.; Coscia, M.; Rambaldi, A.; Montserrat, E.; Foa, R.; Cuneo, A.; Stamatopoulos, K.; Ghia, P.. - In: LEUKEMIA. - ISSN 0887-6924. - 35:12(2021), pp. 3444-3454. [10.1038/s41375-021-01450-8]
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Marasca R.;
2021
Abstract
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
| File | Dimensione | Formato | |
|---|---|---|---|
|
s41375-021-01450-8.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
1.62 MB
Formato
Adobe PDF
|
1.62 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
